Skip to main content
. 2015 Nov;13(6):545–553. doi: 10.1370/afm.1838

Table 5.

Intention-to-Treat Analysis of Secondary Outcomes

Outcome Intervention Group Control Group Adjusteda Odds Ratio or Mean Difference (95% CI) P Value
Drug-specific outcomes
Proton pump inhibitor, No. (%)
 Baseline 53 (53.5) 65 (67.7)
 Intervention completion 23 (23.2) 46 (47.4) 0.30 (0.14–0.68) .04
Duplicate, No. (%)
 Baseline 19 (19.2) 13 (13.5)
 Intervention completion 11 (11.1) 11 (11.3) 0.83 (0.32–2.13) .99
Long-term benzodiazepines,
 No. (%)
 Baseline 14 (14.1) 8 (8.1)
 Intervention completion 9 (9.1) 9 (9.1) 1.31 (0.47–3.68) .99
Patient-reported outcomes
WBQ-12 score: mean well-beingb
 Baseline 24.3 24.4
 Intervention completion 23.6 24.0 –0.41 (−0.80 to 1.07) .99
BMQ score: median necessity-concern differentialc
 Baseline 7.0 5.8
 Intervention completion 6.0 6.0 0.16 (−1.85 to 1.07) .99

BMQ = Beliefs About Medicine Questionnaire; WBQ-12 = 12-item Well-Being Questionnaire.

Note: Figures are numbers (percentages) unless stated otherwise. The Bonferroni method was used to account for multiple comparisons.

a

Adjusted for age, sex, baseline number of PIP drugs, baseline number of repeat medications, number of general practitioners, and practice location.

b

Well-being score ranges from 0 to 36 (1–12 low, 13–24 medium, 25–36 high).

c

Scale from −20 to 20, where positive scores indicate benefits outweigh risks.